| 发明名称 |
Combination Therapy for Ovarian Cancer |
| 摘要 |
The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine. |
| 申请公布号 |
US2014302174(A1) |
申请公布日期 |
2014.10.09 |
| 申请号 |
US201214354244 |
申请日期 |
2012.10.31 |
| 申请人 |
Eli Lilly and Company |
发明人 |
Chan Edward Michael;Pratt Susan Elizabeth;Stancato Louis Frank |
| 分类号 |
A61K33/24;A61K31/437;A61K31/282;A61K31/7068 |
主分类号 |
A61K33/24 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating ovarian cancer in a mammal comprising administering a combination of gemcitabine, a platinum agent selected from the group consisting of cisplatin and carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine or a pharmaceutically acceptable salt. |
| 地址 |
Indianapolis IN US |
